Cover Image

RNA interference targeting ETS-1 downregulates RRM2 and enhances gemcitabine sensitivity in pancreatic cancer cells

Amit Khanna*, Vikram Reddy E.


Aberrant expression of the Ets-1 transcription factor is increasingly associated with the progression of several human cancers. Previously we reported Ets-1 over-expression in gemcitabine resistance pancreatic cancer cell lines. In the present study, we identified Ribonucleotide reductase–M2 subunit, a key enzyme involved in the DNA synthesis is elevated in gemcitabine-resistant PANC1 cells. Silencing of Ets-1 expression in resistant cell line diminishes the Ribonucleotide reductase–M2 expression. The RAS/ERK pathway is commonly activated in carcinomas and promotes oncogenesis by altering transcriptional programs. Ets-1 silencing abrogates the expression of Ribonucleotide reductase–M2 levels in parental cells treated with epidermal growth factor to further activate the RAS/ERK pathway. Our findings clearly demonstrate the involvement of RAS/ERK-mediated Ets-1 pathway in the development of gemcitabine resistance by over-expressing Ribonucleotide reductase–M2.


Ets-1, Gemcitabine, RRM1, RRM2, PANC1, EGF, U0126



  • There are currently no refbacks.

Copyright (c) 2016 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.